We are a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to our mission is the Recursion Operating System that combines an advanced infrastructure layer to generate what we believe is one of the world’s largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms and machine learning (AI) tools. We use those tools to explore foundational biology unconstrained by human bias and navigate to new biological insights that may accelerate our programs.

We expect to initiate Phase 2 clinical trials within the next four to five quarters for these four drug pipeline treatment programs: which were discovered via our Recursion Operating System: 1. REC-4881, an oral treatment for FAP, a rare tumor condition that can cause colon cancer; REC-3599 to treat GM2 gangliosidosis; REC-2282 to treat neurofibromatosis type 2 (NF2) – Phase 2/3 initiation expected within the next four to five quarters, and REC-994 to treat cerebral cavernous malformation (CCM). 

(Note: Recursion Pharmaceuticals upsized its IPO again at pricing on April 15. 2021: 24.24 million shares – up from 22 million shares in its upsized S-1/A filing – were priced at $18 – the top of its $16-to-$18 range. Early on April 15, 2021, the company had increased the size of the deal to 22 million shares – up from 18 million shares initially – in an S-1/A filing.)